Interní Med. 2012; 14(5): 221-223

Celiac disease - from screening to diagnosis

MUDr.Jiří Latta
Interní klinika IPVZ, KNTB Zlín

Celiac disease is poorly diagnosed in Czech population, mostly after a long duration of the disease. Undiagnosed celiac disease often

leads to the development of osteoporosis, autoimmune disorders and malignant diseases. People with celiac disease, where the disease

hasn´t been diagnosed, have almost four times increased mortality compared to serum negative persons. The introduction of targeted

screening is an essential step to limiting the negative consequences of unrecognized disease. The persons indicated for celiac disease

screening a quantitative test for antibodies against tissue transglutaminase and total IgA is performed. A pathological value of the test

indicates the performance of gastroscopy with a biopsy of the aboral duodenum mucosa. After the histological examination using the

Marsh classification, the following steps can be taken: testing antibodies against endomysium; differential diagnosis of excluding any

disease mimicking celiac disease; genetic testing and confirmation of diagnosis using a positive clinical and serological response to

a gluten – free diet.

histology, genetics.

Keywords: celiac disease, target screening, clinical forms of celiac disease, antibodies against tissue transglutaminase and endomysium,

Published: May 14, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Latta J. Celiac disease - from screening to diagnosis. Interní Med. 2012;14(5):221-223.
Download citation

References

  1. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spektrum. Gastroenterology 2001; 120: 636-651. Go to original source... Go to PubMed...
  2. Rostom A, Murray JA, Kagnoff MF. AGA Institute Technical Review on the Diagnosis and Management of Celiac Disease. Gastroenterology 2006; 131: 1981-2002. Go to original source... Go to PubMed...
  3. National Institutes of Health Consensus Development Conference Statement on Celiac Disease, une 28-30, 2004, Gastroenterology 2005; 128(Suppl 1): S1-S9. Go to PubMed...
  4. Frič P, Bušinová I. Celiakie - pohled z druhé strany. Interní Med. 2008, 10(10): 482-484.
  5. Rubio - Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac dinase. Gastroenterology 2009; 137(7): 88-93. Go to original source... Go to PubMed...
  6. Frič P. Komplikace celiakální sprue. Čes. a slov. Gastroenterol. a Hepatol. 2001; 55(1): 26-30.
  7. Frič P, Nevoral J. Cílený screening celiakie. Interní Med. 2009; 11(11): 484-487.
  8. Cílený screening celiakie (metodický pokyn). Věstník MZ ČR, částka 3: 51-54.
  9. Sblattero D, Berti I, Trevisiol C, et al. Human recombinant Tissue transglutaminase ELISA: an innovative diagnostic assay for celiac disease. Am J Gastroenterol 2000; 95(5): 1253-1257. Go to original source... Go to PubMed...
  10. Vecchi M, Folli C, Donato MF, et al. High rate of positive anti-tissue transglutaminase antibodies in chronic liver disease. Scand. J. Gastroenterol. 2003; 38: 50-54. Go to original source... Go to PubMed...
  11. Kotalová R, Nevoral J, Šmídová J. Tkáňové protilátky v diagnostice celiakální sprue. Čs Pediatr. 1996; 51(11): 680-687.
  12. Oxentenko AS, Grisolano SW, Murray JA, et al. The insensitivity of endoscopic markers in celiac disease. Am. J. Gastroenterol, 2002; 97: 933-938. Go to original source... Go to PubMed...
  13. Marsh MN. Gluten, major histocompatibility komplex, and the small intestine: a molecular and immunobiologic approach to the spektrum of gluten senzitivity (celiac sprue). Gastroenterology 1992; 102: 330-354. Go to original source...
  14. Biagi F, Luinetti O, Campanella J, et al. Intraepithelial lymphocytes in the vilous tip: do they indicie potential coeliac disease? J.Clin. Pathol. 2004; 57: 835-839. Go to original source... Go to PubMed...
  15. Verres B, Franzén L, Bodin L, et al. Duodenal intraepithelial lymfocyte - count revisited. Scand J Gastroenterol 2004; 39: 138-144. Go to original source... Go to PubMed...
  16. Walker MM, Murray JA, Ronkainen J, et al. Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population - based study. Gastoenterology 2010; 139: 112-119. Go to original source... Go to PubMed...
  17. Greco L, Corraza G, Babron MC, et al. Genome search in celiac disease. Am. J. Hum. Genet. 1998; 62: 669-675. Go to original source... Go to PubMed...
  18. Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. Am. J. Gastroenterol. 2008; 103: 190-195. Go to original source... Go to PubMed...
  19. Walker - Smith JA, Guandalini S, Schmitz J, et al. Revisid criterie for diagnosis of coeliac disease. Arch Dis Child 1990; 65: 909-911. Go to original source...
  20. Biagi F, Bianchi PI, Campanella J, et al. The impact of misdiagnosing celiac disease at a referral centre. Can. J. Gastroenterol. 2009; 23: 543-545. Go to original source... Go to PubMed...
  21. Collin P, Kaukinen K, Vogelsang H, et al. Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac diseaese: a biopsy - proven European multicentre study. Eur. J. Gastroenterol. Hepatol. 2005; 17: 85-91. Go to original source... Go to PubMed...
  22. Vivas S, Ruis de Morales JG, Riestra S, et al. Duodenal biopsy may be avoided when high transglutaminase antibody titers are present. J. Gastroenterol. 2009; 15: 4775-4780. Go to original source...
  23. Sapone A, Bai JC, Ciacci C, et al. Spectrum of gluten - related disorders: consensus on new nomenclature and classification. BMC Med. 2012; 10: 13. Go to original source... Go to PubMed...
  24. Karell K, Louka AS, Moodie SJ, et al. HLA types in celiac disease patiens not carrying the DQA1 05- DQB1 02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol. 2003; 64(4): 469-477. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.